What Uzedy (paliperidone palmitate) dose should be administered every two months for a patient taking risperidone 2 mg twice daily?

Uzedy Dosing for Patients on Risperidone 2mg BID

For a patient taking risperidone 2mg twice daily (4mg total daily), initiate Uzedy at 100mg once monthly OR 200mg every 2 months via subcutaneous injection in the abdomen or upper arm. 1

Dosing Conversion Algorithm

The FDA-approved Uzedy prescribing information provides explicit conversion tables based on total daily oral risperidone dose 1:

Your patient's current regimen:

• Risperidone 2mg BID = 4mg total daily dose

Corresponding Uzedy doses:

• Once monthly option: 100mg
• Every 2 months option: 200mg

Critical Implementation Steps

Pre-Initiation Requirements

• Tolerability must be established with oral risperidone before starting Uzedy 1
• Since your patient is already on risperidone 2mg BID, tolerability is confirmed

Timing of First Injection

• Administer the first Uzedy injection the day after the last oral risperidone dose 1
• No loading dose required
• No oral supplementation needed 1

Administration Specifics

• Route: Subcutaneous only (abdomen or upper arm) 1
• Must be administered by healthcare professional 1
• Never administer by any other route 1

Choosing Between Monthly vs Every 2 Months

Both dosing intervals are FDA-approved for schizophrenia 1:

Once monthly (100mg):

• More frequent monitoring opportunities
• Easier dose adjustments if needed
• Smaller volume per injection

Every 2 months (200mg):

• Greater convenience for patient
• Fewer clinic visits
• Equivalent steady-state exposure 1

Patients can switch between these regimens by administering the first dose of the new schedule on the next scheduled date of the original regimen 1.

Missed Dose Management

If a dose is missed 1:

• Administer the next injection as soon as possible
• Do not administer more frequently than the recommended interval
• Continue with the regular schedule thereafter

Important Monitoring Considerations

Metabolic Effects

The 2025 INTEGRATE guidelines emphasize that when using antipsychotics with poor cardiometabolic profiles, metformin should be offered concomitantly to attenuate weight gain 2. While this specifically references olanzapine and clozapine, risperidone formulations also carry metabolic risk.

Extrapyramidal Symptoms

Early psychosis guidelines note that risperidone can cause extrapyramidal symptoms even at 2mg daily 3. Monitor for:

• Parkinsonism
• Akathisia
• Dystonia
• Tardive dyskinesia (particularly with long-acting formulations) 4

Hyperprolactinemia

Long-standing hyperprolactinemia associated with hypogonadism can lead to decreased bone density in both females and males 1. This is particularly relevant with risperidone/paliperidone formulations.

Special Populations

Renal Impairment

If creatinine clearance 50-80 mL/min 1:

• Titrate with oral risperidone to at least 2mg once daily first
• Then initiate Uzedy at 50mg once monthly only
• Every 2 month dosing not recommended in renal impairment

Hepatic Impairment

• Mild to moderate: No dose adjustment needed 1
• Severe: No data available; use caution

Drug Interactions

Strong CYP2D6 inhibitors (fluoxetine, paroxetine) 1:

• Place patients on lower Uzedy dose before starting the inhibitor
• If already on 50mg monthly or 100mg every 2 months, continue these doses unless clinical judgment necessitates interruption

Strong CYP3A4 inducers (carbamazepine) 1:

• Monitor closely during first 4-8 weeks
• May need dose increase or supplemental oral risperidone

Common Pitfalls to Avoid

1. Do not use loading doses - The FDA-approved regimen does not require loading 1
2. Do not provide oral supplementation at initiation (unlike some other LAIs) 1
3. Do not administer intramuscularly - Uzedy is subcutaneous only, unlike paliperidone palmitate IM formulations 1
4. Do not assume dose equivalence with paliperidone palmitate IM - These are different formulations with different pharmacokinetics 5